The story has been updated to include comments from a conference call.

NEW YORK (GenomeWeb News) – Exact Sciences said today that revenues in the third quarter came in flat year over year as the firm matched consensus Wall Street estimates on the top and bottom line.

For the three months ended Sept. 30, revenues of $1.0 million were even with the year-ago figure and matched the average analyst estimate of $1.0 million. All revenues came from licensing fees both in the most recently concluded quarter and the year-ago period.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.